Abstract:Antimalarial drug resistance has thrown a spanner in the works of malaria elimination. New drugs are required for ancillary support of existing malaria control efforts. Plasmodium falciparum requires host glucose for survival and proliferation. On this basis, P . falciparum hexose transporter 1 ( Pf HT1) protein involved in hexose permeation is considered a potential drug target. In this study, we tested the antimalarial activity of some compounds against Pf HT1 using computational techniques. We performed high throughput virtual screening of 21,352 small-molecule compounds against Pf HT1. The stability of the lead compound complexes was evaluated via molecular dynamics (MD) simulation for 100 nanoseconds. We also investigated the pharmacodynamic, pharmacokinetic and physiological characteristics of the compounds in accordance with Lipinksi rules for drug-likeness to bind and inhibit Pf HT1. Molecular docking and free binding energy analyses were carried out using Molecular Mechanics with Generalized Born and Surface Area (MMGBSA) solvation to determine the selectivity of the hit compounds for Pf HT1 over the human glucose transporter (hGLUT1) orthologue. Five important Pf HT1 inhibitors were identified: Hyperoside (CID5281643); avicularin (CID5490064); sylibin (CID5213); harpagoside (CID5481542) and quercetagetin (CID5281680). The compounds formed intermolecular interaction with the binding pocket of the Pf HT1 target via conserved amino acid residues (Val314, Gly183, Thr49, Asn52, Gly183, Ser315, Ser317, and Asn48). The MMGBSA analysis of the complexes yielded high free binding energies. Four (CID5281643, CID5490064, CID5213, and CID5481542) of the identified compounds were found to be stable within the Pf HT1 binding pocket throughout the 100 nanoseconds simulation run time. The four compounds demonstrated higher affinity for Pf HT1 than the human major glucose transporter (hGLUT1). This investigation demonstrates the inhibition potential of sylibin, hyperoside, harpagoside, and avicularin against Pf HT1 receptor. Robust preclinical investigations are required to validate the chemotherapeutic properties of the identified compounds.

Structural Basis for Blocking Sugar Uptake into the Malaria Parasite Plasmodium falciparum

Orthosteric-allosteric dual inhibitors of PfHT1 as selective anti-malarial agents

PfHT1 controls glucose uptake in malaria parasite: molecular dynamics study in plasma membrane like environment reveals ligand induced conformational changes trigger closed conformation and alters binding pocket geometry

The molecular basis for sugar import in malaria parasites

Orthosteric–allosteric dual inhibitors of PfHT1 as selective antimalarial agents

Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors.

Functional characterization of Plasmodium vivax hexose transporter 1

An in silico quest for next-generation antimalarial drugs by targeting Plasmodium falciparum hexose transporter protein: a multi-pronged approach

Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism

Structural basis of the substrate recognition and inhibition mechanism of Plasmodium falciparum nucleoside transporter PfENT1

Target Elucidation by Cocrystal Structures of Nadh-Ubiquinone Oxidoreductase of Plasmodium Falciparum (pfndh2) with Small Molecule to Eliminate Drug-Resistant Malaria

Pyruvate Kinase from Plasmodium Falciparum: Structural and Kinetic Insights into the Allosteric Mechanism

A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.

The X-ray Structure Ofplasmodium Falciparumdihydroorotate Dehydrogenase Bound to a Potent and Selectiven-Phenylbenzamide Inhibitor Reveals Novel Binding-Site Interactions

The Cytoplasmic Prolyl-Trna Synthetase of the Malaria Parasite is a Dual-Stage Target of Febrifugine and Its Analogs.

Healthy sweet inhibitor of Plasmodium falciparum aquaglyceroporin

A Class of Tricyclic Compounds Blocking Malaria Parasite Oocyst Development and Transmission

In silico screening of selective ATP mimicking inhibitors targeting the Plasmodium falciparum Grp94

Dynamic Structure and Inhibition of a Malaria Drug Target: Geranylgeranyl Diphosphate Synthase

Addressing the Intracellular Vestibule of the Plasmodial Lactate Transporter PfFNT by p-Substituted Inhibitors Amplifies In Vitro Activity

High Target Homology Does Not Guarantee Inhibition: Aminothiazoles Emerge as Inhibitors of Plasmodium falciparum